{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:54:56Z","timestamp":1789512896319,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,7,11]],"date-time":"2005-07-11T00:00:00Z","timestamp":1121040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2005,7,11]],"date-time":"2005-07-11T00:00:00Z","timestamp":1121040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Background<\/jats:title>\n                        <jats:p>Alendronate has been found to reduce the risk of fractures in postmenopausal women as demonstrated in multiple randomized controlled trials enrolling thousands of women. Yet there is a paucity of such randomized controlled trials in osteoporotic men. Our objective was to systematically review the anti-fracture efficacy of alendronate in men with low bone mass or with a history of prevalent fracture(s) and incorporate prior knowledge of alendronate efficacy in women in the analysis.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>We examined randomized controlled trials in men comparing the anti-fracture efficacy of alendronate to placebo or calcium or vitamin D, or any combination of these. Studies of men with secondary causes of osteoporosis other than hypogonadism were excluded. We searched the following electronic databases (without language restrictions) for potentially relevant citations: Medline, Medline in Process (1966-May 24\/2004), and Embase (1996\u20132004). We also contacted the manufacturer of the drug in search of other relevant trials. Two reviewers independently identified two trials (including 375 men), which met all inclusion criteria. Data were abstracted by one reviewer and checked by another. Results of the male trials were pooled using Bayesian random effects models, incorporating prior information of anti-fracture efficacy from meta-analyses of women.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>The odds ratios of incident fractures in men (with 95% credibility intervals) with alendronate (10 mg daily) were: vertebral fractures, 0.44 (0.23, 0.83) and non-vertebral fractures, 0.60 (0.29, 1.44).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusion<\/jats:title>\n                        <jats:p>In conclusion, alendronate decreases the risk of vertebral fractures in men at risk. There is currently insufficient evidence of a statistically significant reduction of non-vertebral fractures, but the paucity of trials in men limit the statistical power to detect such an effect.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/1471-2474-6-39","type":"journal-article","created":{"date-parts":[[2005,7,12]],"date-time":"2005-07-12T06:26:02Z","timestamp":1121149562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Does Alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women"],"prefix":"10.1186","volume":"6","author":[{"given":"Anna M","family":"Sawka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amiram","family":"Gafni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lehana","family":"Thabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,7,11]]},"reference":[{"issue":"8","key":"152_CR1","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s001980070066","volume":"11","author":"SA Jackson","year":"2000","unstructured":"Jackson SA, Tenenhouse A, Robertson L: Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int. 2000, 11 (8): 680-687.","journal-title":"Osteoporos Int"},{"issue":"4","key":"152_CR2","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1210\/er.2001-2002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G: Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002, 23 (4): 508-16.","journal-title":"Endocr Rev"},{"issue":"4","key":"152_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1210\/er.2001-1002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Tugwell P, Wells G, Guyatt G: Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev. 2002, 23 (4): 496-507.","journal-title":"Endocr Rev"},{"issue":"4","key":"152_CR4","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1210\/er.2001-9002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C: Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002, 23 (4): 570-578.","journal-title":"Endocr Rev"},{"issue":"5 Suppl","key":"152_CR5","doi-asserted-by":"publisher","first-page":"505S","DOI":"10.1016\/8756-3282(95)00258-4","volume":"17","author":"BL Riggs","year":"1995","unstructured":"Riggs BL, Melton LJ: The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone. 1995, 17 (5 Suppl): 505S-511S.","journal-title":"Bone"},{"issue":"2","key":"152_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/BF02738966","volume":"6","author":"NH Bell","year":"1997","unstructured":"Bell NH, Johnson RH: Bisphosphonates in the treatment of osteoporosis. Endocrine. 1997, 6 (2): 203-206.","journal-title":"Endocrine"},{"issue":"38","key":"152_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4380","volume":"4","author":"DJ Spiegelhalter","year":"2000","unstructured":"Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR: Bayesian methods in health technology assessment: a review. Health Technol Assess. 2000, 4 (38): 1-130.","journal-title":"Health Technol Assess"},{"key":"152_CR8","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/bmj.319.7208.508","volume":"319","author":"DJ Spiegelhalter","year":"1999","unstructured":"Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR: Methods in health service research: An introduction to bayesian methods in health technology assessment. BMJ. 1999, 319: 508-512.","journal-title":"BMJ"},{"key":"152_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/0470092602.ch1","volume-title":"Bayesian Approaches to Clinical Trials and Health-Care Evaluation","author":"DJ Spiegelhalter","year":"2004","unstructured":"Spiegelhalter DJ, Abrams KR, Myles JP: Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Edited by: Senn S and Barnett V. 2004, West Sussex: John Wiley and Sons, 1-391. First","edition":"First"},{"key":"152_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/9780470693926.ch5","volume-title":"Systematic Reviews in Health Care: Meta-analysis in Context","author":"P Juni","year":"2001","unstructured":"Juni P, Altman DG, Egger M: Assessing the Quality of Randomised Controlled Trials. Systematic Reviews in Health Care: Meta-analysis in Context. Edited by: Egger M, Smith GD, Altman DG. 2001, London, UK: BMJ Books, 87-108."},{"issue":"9","key":"152_CR11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"E Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A: Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000, 343 (9): 604-10.","journal-title":"N Engl J Med"},{"issue":"2","key":"152_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00296-003-0388-y","volume":"24","author":"JD Ringe","year":"2004","unstructured":"Ringe JD, Dorst A, Faber H, Ibach K: Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int. 2004, 24 (2): 110-3.","journal-title":"Rheumatol Int"},{"issue":"3","key":"152_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s001980200013","volume":"13","author":"JD Ringe","year":"2002","unstructured":"Ringe JD, Orwoll E, Daifotis A, Lombardi A: Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int. 2002, 13 (3): 195-9.","journal-title":"Osteoporos Int"},{"issue":"11","key":"152_CR14","doi-asserted-by":"publisher","first-page":"5252","DOI":"10.1210\/jcem.86.11.7988","volume":"86","author":"JD Ringe","year":"2001","unstructured":"Ringe JD, Faber H, Dorst A: Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab. 2001, 86 (11): 5252-5255.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"152_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00223-002-1085-7","volume":"73","author":"S Gonnelli","year":"2003","unstructured":"Gonnelli S, Cepollaro C, Montagnani A, Bruni D, Caffarelli C, Breschi M, Gennari L, Gennari C, Nuti R: Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int. 2003, 73 (2): 133-139.","journal-title":"Calcif Tissue Int"},{"issue":"13","key":"152_CR16","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa035725","volume":"349","author":"JS Finkelstein","year":"2003","unstructured":"Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003, 349 (13): 1216-1226.","journal-title":"N Engl J Med"},{"issue":"12","key":"152_CR17","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1359\/jbmr.2002.17.12.2247","volume":"17","author":"CE van der Poest","year":"2002","unstructured":"van der Poest CE, van Engeland M, Ader H, Roos JC, Patka P, Lips P: Alendronate in the prevention of bone loss after a fracture of the lower leg. J Bone Miner Res. 2002, 17 (12): 2247-2255.","journal-title":"J Bone Miner Res"},{"issue":"9","key":"152_CR18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0011-393X(02)80065-0","volume":"63","author":"K Kushida","year":"2002","unstructured":"Kushida K, Shiraki M, Nakamura I, Kishimoto H, Morii H, Yamamoto K, Kaneda K, Fukunaga M, Inoue T, Nakashima M, Orimo H: The efficacy of Alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: A randomzed, double-blind, active-controlled, double-dummy trial. Curr Ther Res Clin E. 2002, 63 (9): 606-620.","journal-title":"Curr Ther Res Clin E"},{"issue":"2","key":"152_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/PL00004182","volume":"11","author":"YV Ho","year":"2000","unstructured":"Ho YV, Frauman AG, Thomson W, Seeman E: Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int. 2000, 11 (2): 98-101.","journal-title":"Osteoporos Int"},{"key":"152_CR20","first-page":"210","volume-title":"Seeing Through Statistics","author":"JM Utts","year":"1999","unstructured":"Utts JM: Chapter 2. Seeing Through Statistics. Edited by: Utts JM. 1999, Pacific Grove, CA: Brooks-Cole\/Duxbury Press, 210-Second","edition":"Second"},{"key":"152_CR21","first-page":"178","volume-title":"Mathematical Statistics and Data Analysis","author":"JA Rice","year":"1995","unstructured":"Rice JA: Mathematical Statistics and Data Analysis. 1995, Belmont, CA: Duxbury Press, 178-Second","edition":"Second"},{"key":"152_CR22","first-page":"1212","volume":"24","author":"HK Genant","year":"1997","unstructured":"Genant HK: Assessment of vertebral fractures in osteoporosis research. J Rheumatol. 1997, 24: 1212-1214.","journal-title":"J Rheumatol"},{"key":"152_CR23","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1210\/er.2001-8002","volume":"23","author":"EA Papadimitropoulos","year":"2002","unstructured":"Papadimitropoulos EA, Wells G, Gillespie W, Weaver B, Zytaruk N, Cranney A, Adachi J, Tugwell P, Josse R, Greenwood C, Guyatt G: Meta-analyses of therapies for postmenopausal osteoporosis. VII: Meta-analysis of the efficacyof vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev. 2002, 23: 560-569.","journal-title":"Endocr Rev"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-6-39.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/1471-2474-6-39\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-6-39","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-6-39.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T12:45:12Z","timestamp":1728305112000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/1471-2474-6-39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,11]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2005,12]]}},"alternative-id":["152"],"URL":"https:\/\/doi.org\/10.1186\/1471-2474-6-39","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,11]]},"assertion":[{"value":"27 September 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"39"}}